Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2023-05, Vol.13 (1), p.65-65, Article 65
Hauptverfasser:	Palandri, Francesca, Elli, Elena M., Auteri, Giuseppe, Bonifacio, Massimiliano, Benevolo, Giulia, Heidel, Florian H., Paglia, Simona, Trawinska, Malgorzata M., Bosi, Costanza, Rossi, Elena, Tiribelli, Mario, Tieghi, Alessia, Iurlo, Alessandra, Polverelli, Nicola, Caocci, Giovanni, Binotto, Gianni, Cavazzini, Francesco, Beggiato, Eloise, Cilloni, Daniela, Tatarelli, Caterina, Mendicino, Francesco, Miglino, Maurizio, Bocchia, Monica, Crugnola, Monica, Mazzoni, Camilla, Romagnoli, Andrea D., Rindone, Giovanni, Ceglie, Sara, D’Addio, Alessandra, Santoni, Eleonora, Cattaneo, Daniele, Bartoletti, Daniela, Lemoli, Roberto M., Krampera, Mauro, Cuneo, Antonio, Semenzato, Gianpietro C., Latagliata, Roberto, Abruzzese, Elisabetta, Vianelli, Nicola, Cavo, Michele, Andriani, Alessandro, De Stefano, Valerio, Palumbo, Giuseppe A., Breccia, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2779/109 692/699/1541/1990/2331 Biomedical and Life Sciences Biomedicine Cancer Research Correspondence COVID-19 Hematology Humans Myeloproliferative Disorders Nitriles Oncology Pyrazoles - therapeutic use Pyrimidines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!